Drug
CUTAQUIG
CUTAQUIG is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Completed1
unknown1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (100.0%)
Trials by Status
completed133%
unknown133%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruiting
Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.
NCT04354129
completedphase_3
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
NCT03939533
unknown
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
NCT05986734
Clinical Trials (3)
Showing 3 of 3 trials
NCT04354129
Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.
NCT03939533Phase 3
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
NCT05986734
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3